Ix Biopharma Ltd. (42C)

Overview

iX Biopharma Ltd., rooted in Singapore and extending its operations across Europe, the United States, China, and Australia, stands as a pioneering entity in the realm of specialty pharmaceutical and nutraceuticals. The company is devoted to the development, manufacture, and commercialization of a wide spectrum of therapies aimed at acute and breakthrough pain, among other health concerns. It distinctly operates through two primary segments: Pharmaceutical and Nutraceutical, each dedicated to addressing specific health and wellness needs through innovative drug delivery systems and product formulations.

Products and Services

• Wafermine: A trailblazing sublingual ketamine wafer, already past phase-2 clinical trials for treating acute moderate to severe pain and complex regional pain syndrome, showing promise for pain management beyond traditional methods.
• Xativa & Hypera: Sublingual cannabidiol and tetrahydrocannabinol wafers respectively, designed for the treatment of anxiety, chronic pain, inflammation, and insomnia. These products harness the therapeutic potentials of cannabinoids for various conditions.
• Wafesil & Silcap: These products offer new hope for male erectile dysfunction through sublingual delivery, promising rapid onset of action and enhanced patient convenience over existing oral therapies.
• LumeniX: A sublingual glutathione wafer targeting skin brightening and enhanced immunity, tapping into the growing market for skin care and wellness products that also offer health benefits.
• Radiance, Regenerate, WafeRest, & SL-NAD+ Supplement Products: A line of nutraceuticals aimed at improving skin appearance, cellular health, energy production, alleviation of jet lag, and promotion of restorative sleep. These products reflect the company's commitment to holistic health, combining scientific innovation with natural elements.
• Development Projects: The company is actively engaged in the development of cutting-edge therapeutics, including BnoX (a sublingual buprenorphine wafer for moderate to severe pain management), Dexmedetomidine (for agitation in dementia), Dronabinol (for chemotherapy-induced issues), IXB-214 (for complex regional pain syndrome), IXB-314 (for treatment-resistant depression), IXB-321 (a sublingual vaccine wafer), iXB-322 (for respiratory viral prophylaxis), and iXB-320 (for anorexia in HIV/chemoinduced nausea and vomiting). These projects represent iX Biopharma's ongoing investment in addressing unmet medical needs through innovative pharmaceutical candidates.